CURRICULUM VITAE

Ao. Univ.-Prof. Dr. Georg WEINLICH, M. D.

Clinical Department of Dermatology and Venerology
Medical University of Innsbruck, Austria
Anichstr. 35., A-6020 Innsbruck, Austria, Europe

Date/Place of birth:	27.02.1962, Vienna, Austria
Parents:	Arch.Univ.Prof.Dr.Tech.Robert Weinlich
	Ilse Weinlich, geb. Fitz
Marital Status:	Divorced
Religion:	Roman catholic
Present Address:	A-6020 Innsbruck, Anton-Rauchstr. 8c / W55b
	Tel: 0043/(0)664 - 1635293

EDUCATION

1968-1970	Elementary School Vienna
1970-1972	Elementary School Innsbruck
1972-1980	High School, Innsbruck
10.6.1980	Matriculation
1980-1988	Faculty of Medicine Innsbruck
15.10.1988	Graduation to Doctor of Medicine

ACADEMIC CAREER

1986-87	Theses at the Dept. of Dermatology Innsbruck - "The role of epidermal Langerhans-Cells in the phase of induction of contactallergologic reactions"
1988	Theses-Award of the Austrian Society for Immunology and Allergy
1983-89	Residency, Dept. of Anatomy Innsbruck
1989-90	Karl-Landsteiner-Scholarship at SANDOZ-Research-Center Vienna (Dermatologic research)
1990-94	Residency General Medicine, Innsbruck - Nomination to General Practitioner 01.04.94
1993	Course for Emergency Medicine and Intensive Care
since 01.04.1993	Residency (Department of Dermatology, Medical University of Innsbruck) – since 17.02.2000 Specialist in Dermatology
since 15.03.2007	“venia docendi” (Professor for Dermatology and Venerology)
11/2007	Course for Clinical Trial Management, Salzburg

CLINICAL DUTIES, CLINIC ORGANIZATION AND STUDENT TEACHING

Clinical activities as set out in the instruction catalogue of the Austrian Society of Dermatology

Leader of the Dermato-Oncology ("Hautkrebszentrum Innsbruck")

Student teaching

Manager of Organization and Clinic of the Clinical Department of Dermatology and Venerology

("Geschäftsführender Oberarzt")

EXPERIENCE IN CLINICAL TRIALS

Principial Investigator or Sub Investigator for Clinical Trails:

SI 2021: Protocol number: BiomeOne
"Pilot Study to investigate the native gut microbial composition and cancer-immunotherapy induced changes in patients with advanced cancer"; Sponsor myBioma GmbH – 1 patient
SI 2019: Protocol number: CA209-76K
"A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma"; Sponsor BMS, EudraCT-Number: 2019-001230-34 – 1 patient
PI 2019: Protocol number: Bering Melanoma (NIS)
"Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING Melanoma"; Sponsor Pierre Fabre, – 1 patient
PI 2019: Protocol number: INCMGA 0012-203
"A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)"; Sponsor Incyte, EudraCT-Number: 2018-002941-12 – 0 patients
SI 2018: Protocol number: MK 3475-587
"A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial"; Sponsor MSD, EudraCT-Number: 2017-004417-42) – 1 patient
PI 2018: Protocol number: COMBI-I CPDR001F2301
"A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, Dabrafenib and Trametinib versus Placebo, Dabrafenib and Trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant Melanoma"; Sponsor Novartis, EudraCT-Number: 2016-002794-35) – 1 patient
PI 2017: Protocol number: R2810-ONC-1620
„A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy"
Sponsor Regeneron Pharmaceuticals, EudraCT-Number: 2016-003122-16 – 0 patients
SI 2017: Protocol number: CO39262 (Trilogy)
" A phase III, double-blinded, randomized, placebo-controlled study of Atezolizumab plus Cobimetinib and Vemurafenib in previously untreated BRAF V600 mutation-positive patients with unresctable locally advanced or metastatic melanoma"; Sponsor F. Hoffmann-La Roche, EudraCT-Number: 2016-00248254) – 1 patient
SI 2017: Protocol number: BMS 209-587 (Nivosquacs)
Sponsor Bristol Myes Squibb IC, EudraCT-Number: 2016-002811-16 – 0 patient
PI 2016: Protocol number: BMS 209-401
"Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma"; Sponsor Bristol Myers Squibb IC, EudraCT-Number: 2015-003199-56) – 3 patients

SI 2016: Protocol Number: 20110265 Masterkey-265

"A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma"; Sponsor Amgen, EudraCT-Number: 2014-004944-37) – 2 patients
SI 2016: Protocol Number: CTMT212AAT01 Datum
Sponsor Novartis, Nicht-Inventionelle Studie (NIS) – 9 patients
SI 2014: Protocol number CA209-172
„A single-arm, open-label, multicenter clinical Trial with Nivolumab (BMS-936558) for subjects with histologically confirmed stage III (unresectable) or stage IV Melanoma progressing post prior treatment containing an anti-CTLA-4 monoclonal antibody, CheckMate 172: CHECKpoint pathway and nivoluMab clinical trial evaluation 172" ; Sponsor Bristol Myers Squibb IC; EudraCT-number: 2014-001286-28 - 2 patients
SI 2013: Protocol number MK3475-006
„A multicenter, randomized, controlled, three-arm, phase III study to evaluate the safety and efficacy of two dosing schedules of MK-3475 compared to Ipilimumab in patient with advanced melanoma." Sponsor Merck Sharp & Dohme Corp. ; EudraCT-number: 2012-004907-10 - 4 patients
SI 2013: Protocol number CMEK162A2301
„The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized phase III, open label, multicenter, two-arm study comparing the efficacy of MEK162 versus Dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma." Sponsor Novartis Pharma GmbH; EudraCT-number: 2012-003593-51 - 1 patient
SI 2013: Protocol number BRF115532 Combi-AD
„A phase III randomized double blind study of Dabrafenib (GSK2118436) in Combination with Trametinib (GSK1120212) versus two placebos in the adjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection." Sponsor GlaxoSmithKline Pharma GmbH; EudraCT-number: 2012-001266-15
SI 2012: Protocol number CA209-037
„A randomized, open-label phase II trial of BMS-936558 (Nivolumab) versus investigator`s choice in advanced (unresectable or metatstatic) Melanoma patients progressing post Anti CTLA-4 Therapy" Sponsor Bristol myers Squipp IC; EudraCT-number: 2012-001828-35
SI 2012: Protocol number MEK116513
„A phase III randomized, open-label study comparing the combination oft he BRAF inhibitor, Dabrafenib and the MEK inhibitor, Trametinib tot he BRAF inhibitor Vemurafenib in subjects with unresectable (stage IIIc) or metastatic (stage IV9 BRAF V600E/K mutation-positive melanoma". Sponsor GlaxoSmithKline Pharma GmbH; EudraCt-number: 2012-004907-10 - 1 patient
SI 2012: Protocol number MO28295
„MIKIE-a randomized, double-blinded, regimen-controlled, phase II, multicenter study to assess the efficacy and safety oft wo different Visomodegib regimens in patients with Multiple Basal Cell Carcinomas" Sponsor F.Hoffmann-La Roche LTD, EudraCT-number: 2012-003305-10 - 2 patients
SI 2011: Protocol number MO25515
„An open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma" Sponsor F. Hoffmann-La Roche LTD; EudraCT-number: 2010-023526-21 - 12 patients
SI 2011: Protocol number GO27826 BRIM8
„A phase III, randomized, double-blind, placebo-controlled study or Vemurafenib (RO51855426) adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence". Sponsor F. Hoffmann-La Roche LTD; EudraCT-number: 2011-004011-24
2015: Named Patient Programs:
GSK 117341: Application for Trametinib & Dabrafenib access under compassionate use Program Sponsor GlaxoSmithKline, 10 patients
MK3475: Expanded access of MK3475 in metastatic melanoma patients with limited to NO treatment options, Sponsor Merck Sharp & Dohme Corp, 10 patients

MEMBERSHIPS

Österreichische Gesellschaft für Dermatologie und Venerologie (ÖGDV)

Secretary of the AMDO – Arbeitsgruppe Melanom und Dermatologische Onkologie

Board Member European Association of Dermato-Oncology (EADO)

European Academy of Dermatology and Venerology (EADV)

PUBLICATIONS

Kofler H, Wambacher B, Topar G, Weinlich G, Schuler G, Hintner H, Romani N, Fritsch P. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita*. J Am Acad Dermatol* 36:331-5, 1997.

Zelger B, Weinlich G, Steiner H, Zelger BG, Egarter-Vigl E. Dermal and subcutaneous variants of plexiform fibrohistiocytic tumor. *Am J Surg Pathol* 21:235-41, 1997

Weinlich G, Heine M, Stössel H, Zanella M, Stoitzner P, Ortner U, Smolle J, Koch F, Sepp N, Schuler G, Romani N. Entry into afferent lymphatics and maturation in situ of migrating murine cutaneous dendritic cells. *J Invest Dermatol* 110:441-8, 1998

Weinlich G, Schuler G, Greil R, Kofler H, Fritsch P. Leg ulcers associated with long-term hydroxyurea therapy. *J Am Acad Dermatol* 39:372-4, 1998.

Schmuth M, Vogel W, Weinlich G, Margreiter R, Fritsch P, Sepp N. Cutaneous lesions as presenting sign of acute graft versus host disease following liver transplantation. *Br J Dermatol*, 141(5): 901-4, 1999

Kruse R, Cichon S, Anker M, Hillmer AM, Barros-Nunez P, Cantu JM, Leal E, Weinlich G, Schmuth M, Fritsch P, Ruzicka T, Propping P, Nöthen MM. Novel hairless mutations in two kindreds with autosomal recessive papular atrichia; *J Invest Dermatol* 113(6): 954-9, 1999.

Reider N, Sepp N, Fritsch P, Weinlich G, Jensen-Jarolim E. Anaphylaxis to camomile: IgE epitopes are heat resistant, non-carbohydrate and crossreacting with vegetable food and pollen extracts; *Clin Exp* Allergy 30: 1436-4, 2000.

Zelger BG, Weinlich G, Zelger B. Perineurioma – a frequently unrecogniced entity with emphasis on a plexiform variant; *Adv Clin Pathology* 4: 25-3, 2000 (not listed).

Schmuth M, Sztankay A, Weinlich G, Linder D, Wimmer M, Fritsch P, Fritsch E. Permeability barrier function of the skin exposed to ionizing radiation; *Arch Dermatol* 137: 1019-1023, 2001.

Schmuth M, Spötl L, Zelger BG, Weinlich G, Zelger B. Clear cells in acral melanoma; *Eur J Dermatol* 11: 21-24, 2001

.

Weinlich G, Doss MO, Sepp N, Fritsch P. Variegate porphyria with coexistent decrease in Porphobilinogen deaminase activity; *Acata Derm Venerol* 81: 356-35, 2001.

Schuler-Thurner B, Schultz E, Berger Th, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch P, Romani N, Schuler G. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells; *J Exp Med* 195(10): 1279-1288, 2002.

Schmuth M, Wimmer M, Hofer S, Sztankay A, Weinlich G, Linder D, Elias P, Fritsch P, Fritsch E. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study; *Br J Dermatol* 146(6): 983-991, 2002.

Weinlich G, Bitterlich W, Mayr V, Fritsch P, Zelger B. Metallothionein – overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients; *Br J Dermatol* 149: 535-54, 2003.

Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch P, Zelger B: Metallothionein – overexpression as a highly significant prognostic factor in melanoma. A prospective study on 1270 patients; *Br J Cancer; 94(6): 835-841,* 2006*.*

Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D. Decreased serum tryptphan concentration predicts poor prognosis in malignant melanoma patients; *Dermatology;* 214(1): 8-14, 2007.

Weinlich G, Topar G, Eisendle K, Fritsch P, Zelger B: Comparison of metallothionein – overexpression with sentinel lymph node biopsy as prognostic factors in melanoma; *J Euro Acad Dermatol;* 21(5): 669-677, 2007.

Weinlich G, Zelger B: Metallothionein overexpression, a highly significant prognostic factor in thin melanoma; *Histopathology;* 51(2): 280-283, 2007.

Thallinger C, Skorjanec S, Soleiman A, Tzaneva S, Griss J, Rous W, Poeppl W, Weinlich G, Karimian-Teherani D, Joukhadar C. Orally administered rapamycin, dacarbazine or both for treatment of human melanoma evaluated in severe combined immunodeficiency mice. *Pharmacology.* 2008;82(3):233-8.

Giehl KA, Rogers MA, Radivojkov M, Tosti A, de Berker DA, Weinlich G, Schmuth M, Ruzicka T, Eckstein GN. Pili annulati: refinement of the locus on chromosome 12q24.33 to a 2.9-Mb interval and candidate gene analysis; *Br J Dermatol.* 2009 Mar;160(3):527-33.

Weinlich G. Metallothionein-overexpression as a prognostic marker in melanoma; *G Ital Dermatol Venereol.* 2009; 144(1): 27-38.

Kühnelt-Leddihn L, Müller H, Eisendle K, Zelger B, Weinlich G. Overexpression of the chemokine receptors CXCR4, CCR7, CCR9, and CCR10 in human primary cutaneous melanoma: a potential prognostic value for CCR7 and CCR10*? Arch Dermatol Res.* 2012 Apr;304(3):185-93.

Ratzinger G, Mitteregger S, Wolf B, Berger R, Zelger B, Weinlich G, Fritsch P, Goebel G, Fiegl H. Association of TNFRSF10D DNA-methylation with the survival of melanoma patients. *Int J Mol Sci.* 2014 Jul 7;15(7):11984-95.

Bale R, Schullian P, Schmuth M, Widmann G, Jaschke W, Weinlich G. Stereotactic Radiofrequency Ablation for Metastatic Melanoma to the Liver. *Cardiovasc Intervent Radiol.* 2016 Aug;39(8):1128-35.

Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, Dummer R, Forsea AM, Hoeller C, Gogas H, Demidov L, Lebbe C, Blank C, Olah J, Bastholt L, Herceg D, Neyns B, Vieira R, Hansson J, Rutkowski P, Krajsova I, Bylaite-Bucinskiene M, Zalaudek I, Maric-Brozic J, Babovic N, Banjin M, Putnik K, Weinlich G, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Kukushkina M, De La Cruz Merino L, Ymeri A, Risteski M, Garbe C. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments*. Eur J Cancer.* 2017 Apr;75:313-322.

Buschow SI, Ramazzotti M, Reinieren-Beeren IMJ, Heinzerling LM, Westdorp H, Stefanini I, Beltrame L, Hato SV, Ellebaek E, Gross S, Nguyen VA, Weinlich G, Ragoussis J, Baban D, Schuler-Thurner B, Svane IM, Romani N, Austyn JM, De Vries IJM, Schuler G, Cavalieri D, Figdor CG. Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. *Oncotarget.* 2017 Jun 27; 8(40):67439-67456.

Philipp M, Rossmann A, Moosbrugger-Martinz V, Steinkohl F, Weinlich G, Schmuth M, Nguyen VA.

Sudden swelling of face and neck following colonoscopy. *J Dtsch Dermatol Ges.* 2018 May; 16(5):609-610.

Philipp M, Frischhut N, Tschachler A, Steinkohl F, Weinlich G, Schmuth M, Nguyen VA. Pseudoprogression with subsequent complete response and severe thrombocytopenia to checkpoint inhibitor immunotherapy in a patient with advanced mucosal melanoma of the sinonasal cavity. *J Anticancer Drugs.* 2018 Oct;29(9):914-918.

De Martino E, Brunetti D, Canzonieri V, Conforti C, Eisendle K, Mazzoleni G, Nobile C, Rao F, Zschocke J, Jukic E, Jaschke W, Weinlich G, Zelger B, Schmuth M, Stanta G, Zanconati F, Zalaudek I, Bonin S. The Association of Residential Altitude on the Molecular Profile and Survival of Melanoma: Results of an Interreg Study. *Cancers* 2020, 12(10), 2796;

Eisendle K, Weinlich G, Ebner S, Forstner M, Reider D, Zelle-Rieser C, Tripp CH, Fritsch P, Stoitzner P, Romani N, Nguyen VA. Combining chemotherapy and autologous peptide-pulsed dendritic cells provides survival benefit in stage IV melanoma patients. *J Dtsch Dermatol Ges.* 2020 Nov;18(11):1270-1277.

Eisendle K, Weinlich G, Ebner S, Forstner M, Reider D, Zelle-Rieser C, Tripp CH, Fritsch P, Stoitzner P, Romani N, Nguyen VA. Kombination von Chemotherapie und autologen, Peptid-beladenen dendritischen Zellen bringt Überlebensvorteil bei Melanompatienten im Stadium IV. *J Dtsch Dermatol Ges.* 2020 Nov;18(11):1270-1279.

Kandolf Sekulovic L, Peris K, Stratigos A, Hauschild A, Forsea AM, Lebbe C, Lallas A, Grob JJ, Harwood C, Gogas H, Rutkowski P, Olah J, Kelleners-Smeets N, Paoli J, Dummer R, Moreno-Ramirez D, Bastholt L, Putnik K, Karls R, Hoeller C, Vandersleyen V, Vieira R, Arenberger P, Bylaite-Buckinskiene M, Ocvirk J, Situm M, Weinlich G, Banjin M, Todorovic V, Ymeri A, Zhukavets A, Garbe C. Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centers in 27 European countries. *J Eur Acad Dermatol Venereol.* 2020 Dec 16.

Innsbruck, ……..... ao.Univ.-Prof. Dr. Georg Weinlich